Your browser is no longer supported. Please, upgrade your browser.
Settings
NBY NovaBay Pharmaceuticals, Inc. daily Stock Chart
NBY [AMEX]
NovaBay Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.33 Insider Own0.50% Shs Outstand27.98M Perf Week2.28%
Market Cap39.41M Forward P/E- EPS next Y-0.15 Insider Trans0.00% Shs Float26.11M Perf Month35.91%
Income-7.90M PEG- EPS next Q-0.06 Inst Own5.40% Short Float0.95% Perf Quarter38.27%
Sales7.00M P/S5.63 EPS this Y-25.30% Inst Trans-2.21% Short Ratio0.06 Perf Half Y77.50%
Book/sh-0.01 P/B- EPS next Y37.50% ROA-69.80% Target Price- Perf Year-32.12%
Cash/sh0.16 P/C6.91 EPS next 5Y- ROE-604.30% 52W Range0.24 - 1.85 Perf YTD75.00%
Dividend- P/FCF- EPS past 5Y42.40% ROI-391.90% 52W High-39.46% Beta3.94
Dividend %- Quick Ratio1.30 Sales past 5Y44.30% Gross Margin71.70% 52W Low366.67% ATR0.11
Employees28 Current Ratio1.40 Sales Q/Q26.70% Oper. Margin-98.10% RSI (14)56.68 Volatility11.08% 12.64%
OptionableNo Debt/Eq- EPS Q/Q76.90% Profit Margin- Rel Volume0.53 Prev Close1.08
ShortableYes LT Debt/Eq- EarningsMay 07 AMC Payout- Avg Volume4.34M Price1.12
Recom1.50 SMA2013.28% SMA5017.92% SMA20057.99% Volume2,268,852 Change3.70%
Sep-18-19Initiated Ladenburg Thalmann Buy $1.10
Jul-06-18Reiterated H.C. Wainwright Buy $4
Nov-15-17Reiterated Laidlaw Buy $10 → $8
Jun-05-17Initiated ROTH Capital Buy $5.50
Mar-27-17Initiated Laidlaw Buy $10
Feb-06-17Initiated Rodman & Renshaw Buy $6
Mar-07-16Downgrade Maxim Group Buy → Hold
Dec-14-15Reiterated Maxim Group Buy $1 → $0.23
Apr-30-15Resumed Maxim Group Buy $2
Mar-06-13Initiated Ascendiant Capital Markets Strong Buy $2.25
Jan-03-08Initiated Dawson James Speculative Buy $8
May-14-20 06:50AM  
May-07-20 04:05PM  
May-05-20 02:05PM  
Apr-27-20 04:15PM  
Apr-20-20 06:50AM  
Mar-26-20 04:05PM  
02:30PM  
Mar-25-20 06:50AM  
Mar-23-20 06:50AM  
Mar-19-20 06:50AM  
Dec-02-19 06:50AM  
Nov-18-19 06:50AM  
Nov-07-19 04:05PM  
Nov-04-19 06:50AM  
Oct-31-19 06:50AM  
Oct-28-19 06:50AM  
Sep-24-19 02:20PM  
06:50AM  
Sep-16-19 06:50AM  
Aug-09-19 09:26AM  
09:22AM  
Aug-07-19 06:50AM  
Jul-29-19 06:50AM  
Jul-15-19 06:50AM  
Jul-01-19 10:17AM  
06:50AM  
Jun-26-19 04:05PM  
Jun-17-19 06:50AM  
Jun-10-19 01:52PM  
07:55AM  
06:50AM  
May-21-19 04:05PM  
May-09-19 04:05PM  
Apr-30-19 06:50AM  
Apr-17-19 06:50AM  
Apr-15-19 06:50AM  
Mar-28-19 04:05PM  
02:30PM  
Mar-12-19 04:05PM  
10:30AM  
Jan-07-19 06:50AM  
Nov-14-18 04:05PM  
Nov-07-18 06:50AM  
Nov-06-18 10:30AM  
Sep-28-18 06:50AM  
Aug-30-18 08:00AM  
Aug-07-18 04:05PM  
02:30PM  
Jul-31-18 06:50AM  
Jul-05-18 06:50AM  
May-10-18 04:05PM  
May-07-18 06:50AM  
Mar-20-18 04:05PM  
12:00PM  
07:41AM  
Mar-01-18 10:49PM  
03:53AM  
Feb-21-18 06:50AM  
Feb-12-18 06:50AM  
Jan-08-18 06:50AM  
Dec-22-17 06:50AM  
Dec-21-17 06:50AM  
Dec-19-17 01:41PM  
Dec-06-17 06:50AM  
Nov-30-17 02:09PM  
Nov-29-17 08:02AM  
Nov-14-17 04:05PM  
11:00AM  
05:01AM  
Nov-07-17 06:50AM  
Sep-26-17 09:00AM  
Sep-20-17 06:50AM  
Sep-19-17 06:10PM  
Sep-18-17 12:01PM  
09:00AM  
Sep-05-17 06:50AM  
Aug-14-17 09:00AM  
Aug-10-17 04:05PM  
02:00PM  
Aug-03-17 06:50AM  
Jul-24-17 10:00AM  
Jul-10-17 01:32PM  
10:00AM  
06:50AM  
Jun-26-17 06:50AM  
Jun-13-17 10:14AM  
May-30-17 06:50AM  
May-19-17 04:05PM  
May-11-17 04:05PM  
May-04-17 06:50AM  
May-02-17 10:00AM  
Apr-17-17 10:00AM  
Mar-29-17 01:04PM  
Mar-28-17 12:47PM  
10:33AM  
10:00AM  
Mar-27-17 08:57AM  
Mar-24-17 10:50AM  
Mar-23-17 04:14PM  
04:05PM  
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.